|Bid||45.09 x 1300|
|Ask||45.19 x 1800|
|Day's Range||44.82 - 45.31|
|52 Week Range||33.53 - 46.86|
|Beta (5Y Monthly)||0.38|
|PE Ratio (TTM)||19.71|
|Forward Dividend & Yield||2.20 (4.80%)|
|Ex-Dividend Date||Nov 18, 2021|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for GSKLearn more
In the latest trading session, GlaxoSmithKline (GSK) closed at $45.25, marking a -1.07% move from the previous day.
In this Motley Fool Live video recorded on Jan. 19, Motley Fool contributors Keith Speights and Brian Orelli discuss whether they think GlaxoSmithKline should have accepted Unilever's offer. Keith Speights: One of the big stories in recent days was that GlaxoSmithKline (NYSE: GSK) revealed that it turned down an offer of more than $68 billion from Unilever (NYSE: UL) to buy the combined consumer health unit of Glaxo and Pfizer (NYSE: PFE).
Gilead (GILD) efforts to build an oncology franchise get jolted as the FDA places hold on a few studies evaluating the combination of magrolimab plus azacitidine.